NEW YORK--(BUSINESS WIRE)--Cartesian Growth Corporation (“Cartesian”) (NASDAQ: GLBL), a publicly traded special purpose acquisition company, today announced the filing with the U.S. Securities and ...
Phase 3 trial of Descartes-08 in myasthenia gravis to start in 1H25 Cartesian Therapeutics has secured an agreement from the US Food and Drug Administration (FDA) under the Special Protocol Assessment ...
일부 결과는 사용자가 액세스할 수 없으므로 숨겨졌습니다.
액세스할 수 없는 결과 표시